|
1
|
Zhang W, Jiang Y, Yu Q, Qiang S, Liang P,
Gao Y, Zhao X, Liu W and Zhang J: EGFR promoter methylation, EGFR
mutation, and HPV infection in Chinese cervical squamous cell
carcinoma. Appl Immunohistochem Mol Morphol. 23:661–666. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ji M, Fan D, Yuan L, Zhang Y, Dong W and
Peng X: EBP50 inhibits pancreatic cancer cell growth and invasion
by targeting the β-catenin/E-cadherin pathway. Exp Ther Med.
10:1311–1316. 2015.PubMed/NCBI
|
|
3
|
Zheng JF, Sun LC, Liu H, Huang Y, Li Y and
He J: EBP50 exerts tumor suppressor activity by promoting cell
apoptosis and retarding extracellular signal-regulated kinase
activity. Amino Acids. 38:1261–1268. 2010. View Article : Google Scholar
|
|
4
|
Clapéron A, Guedj N, Mergey M, Vignjevic
D, Desbois-Mouthon C, Boissan M, Saubaméa B, Paradis V, Housset C
and Fouassier L: Loss of EBP50 stimulates EGFR activity to induce
EMT phenotypic features in biliary cancer cells. Oncogene.
31:1376–1388. 2012. View Article : Google Scholar
|
|
5
|
Molina JR, Agarwal NK, Morales FC, Hayashi
Y, Aldape KD, Cote G and Georgescu MM: PTEN, NHERF1 and PHLPP form
a tumor suppressor network that is disabled in glioblastoma.
Oncogene. 31:1264–1274. 2012. View Article : Google Scholar
|
|
6
|
Peng XL, Ji MY, Yang ZR, Song J and Dong
WG: Tumor suppressor function of ezrin-radixin-moesin-binding
phospho-protein-50 through β-catenin/E-cadherin pathway in human
hepatocellular cancer. World J Gastroenterol. 19:1306–1313. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma Q, Jiao Y, Hao Y, Yan S, Lyu N, Gao H,
Li D, Liu Q, Zheng J and Song N: Targeting of NHERF1 through RNA
interference inhibits the proliferation and migration of metastatic
prostate cancer cells. Oncol Lett. 11:1149–1154. 2016.PubMed/NCBI
|
|
8
|
Bellizzi A, Malfettone A, Cardone RA and
Mangia A: NHERF1/EBP50 in breast cancer: Clinical perspectives.
Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar
|
|
9
|
Song J, Bai J, Yang W, Gabrielson EW, Chan
DW and Zhang Z: Expression and clinicopathological significance of
oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50
in breast cancer. Histopathology. 51:40–53. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cardone RA, Bellizzi A, Busco G, Weinman
EJ, Dell’Aquila ME, Casavola V, Azzariti A, Mangia A, Paradiso A
and Reshkin SJ: The NHERF1 PDZ2 domain regulates
PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor
cells. Mol Biol Cell. 18:1768–1780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shibata T, Chuma M, Kokubu A, Sakamoto M
and Hirohashi S: EBP50, a beta-catenin-associating protein,
enhances Wnt signaling and is over-expressed in hepatocellular
carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kislin KL, McDonough WS, Eschbacher JM,
Armstrong BA and Berens ME: NHERF-1: Modulator of glioblastoma cell
migration and invasion. Neoplasia. 11:377–387. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan J, Zhang Y, Ren C, Shi W and Chen L:
Involvement of nuclear protein C23 in activation of EGFR signaling
in cervical cancer. Tumour Biol. 37:905–910. 2016. View Article : Google Scholar
|
|
14
|
Shostak K, Zhang X, Hubert P, Göktuna SI,
Jiang Z, Klevernic I, Hildebrand J, Roncarati P, Hennuy B, Ladang
A, et al: NF-κB-induced KIAA1199 promotes survival through EGFR
signalling. Nat Commun. 5:52322014. View Article : Google Scholar
|
|
15
|
Bhattacharyya RP, Reményi A, Yeh BJ and
Lim WA: Domains, motifs, and scaffolds: The role of modular
interactions in the evolution and wiring of cell signaling
circuits. Annu Rev Biochem. 75:655–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clapéron A and Therrien M: KSR and CNK:
Two scaffolds regulating RAS-mediated RAF activation. Oncogene.
26:3143–3158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lazar CS, Cresson CM, Lauffenburger DA and
Gill GN: The Na+/H+ exchanger regulatory
factor stabilizes epidermal growth factor receptors at the cell
surface. Mol Biol Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao W, Feng D, Bian W, Yang L, Li Y, Yang
Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced
breast cancer cell proliferation by blocking EGFR phosphorylation.
Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Forni C, Braglia R, Lentini A, Nuccetelli
M, Provenzano B, Tabolacci C and Beninati S: Role of
transglutaminase 2 in quercetin-induced differentiation of B16-F10
murine melanoma cells. Amino Acids. 36:731–738. 2009. View Article : Google Scholar
|
|
20
|
Sun L, Zheng J, Wang Q, Song R, Liu H,
Meng R, Tao T, Si Y, Jiang W and He J: NHERF1 regulates actin
cytoskeleton organization through modulation of α-actinin-4
stability. FASEB J. 30:578–589. 2016. View Article : Google Scholar
|
|
21
|
Yang L, Zheng J, Xiong Y, Meng R, Ma Q,
Liu H, Shen H, Zheng S, Wang S and He J: Regulation of
β2-adrenergic receptor cell surface expression by interaction with
cystic fibrosis trans-membrane conductance regulator-associated
ligand (CAL). Amino Acids. 47:1455–1464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu SF, Qian WY, Zhang JW, Yang YB, Liu Y,
Dong Y, Zhang ZB, Zhu YP and Feng YJ: Network motifs in the
transcriptional regulation network of cervical carcinoma cells
respond to EGF. Arch Gynecol Obstet. 287:771–777. 2013. View Article : Google Scholar
|
|
23
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59(Suppl):
21–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang L, Wang Y, Chen P, Hu J, Xiong Y,
Feng D, Liu H, Zhang H, Yang H and He J: Na(+)/H(+) exchanger
regulatory factor 1 (NHERF1) is required for the
estradiol-dependent increase of phosphatase and tensin homolog
(PTEN) protein expression. Endocrinology. 152:4537–4549. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maudsley S, Zamah AM, Rahman N, Blitzer
JT, Luttrell LM, Lefkowitz RJ and Hall RA: Platelet-derived growth
factor receptor association with Na(+)/H(+) exchanger regulatory
factor potentiates receptor activity. Mol Cell Biol. 20:8352–8363.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan Y, Weinman EJ and Dai JL:
Na+/H+ exchanger regulatory factor 1 inhibits
platelet-derived growth factor signaling in breast cancer cells.
Breast Cancer Res. 10:R52008. View
Article : Google Scholar
|
|
27
|
Wheeler DS, Barrick SR, Grubisha MJ,
Brufsky AM, Friedman PA and Romero G: Direct interaction between
NHERF1 and Frizzled regulates β-catenin signaling. Oncogene.
30:32–42. 2011. View Article : Google Scholar
|
|
28
|
Kreimann EL, Morales FC, de Orbeta-Cruz J,
Takahashi Y, Adams H, Liu TJ, McCrea PD and Georgescu MM: Cortical
stabilization of beta-catenin contributes to NHERF1/EBP50 tumor
suppressor function. Oncogene. 26:5290–5299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He J, Lau AG, Yaffe MB and Hall RA:
Phosphorylation and cell cycle-dependent regulation of
Na+/H+ exchanger regulatory factor-1 by Cdc2
kinase. J Biol Chem. 276:41559–41565. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Noordhuis MG, Eijsink JJ, Ten Hoor KA,
Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de
Bock GH, et al: Expression of epidermal growth factor receptor
(EGFR) and activated EGFR predict poor response to (chemo)radiation
and survival in cervical cancer. Clin Cancer Res. 15:7389–7397.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takahashi Y, Morales FC, Kreimann EL and
Georgescu MM: PTEN tumor suppressor associates with NHERF proteins
to attenuate PDGF receptor signaling. EMBO J. 25:910–920. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim HA, Kim KJ, Seo KH, Lee HK and Im SY:
PTEN/MAPK pathways play a key role in platelet-activating
factor-induced experimental pulmonary tumor metastasis. FEBS Lett.
586:4296–4302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R,
Qian Y, Li Q, Wang L, Shi Z, et al: Alteration in Mir-21/PTEN
expression modulates gefitinib resistance in non-small cell lung
cancer. PLoS One. 9:e1033052014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ,
Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, et al: Activation of
PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop
is involved in rapamycin resistance in hepatocellular carcinoma.
PLoS One. 7:e333792012. View Article : Google Scholar
|
|
35
|
Zheng J, Dai Y, Yang Z, Yang L, Peng Z,
Meng R, Xiong Y and He J: Ezrin-radixin-moesin-binding
phosphoprotein-50 regulates EGF-induced AKT activation through
interaction with EGFR and PTEN. Oncol Rep. 35:530–537. 2016.
|
|
36
|
Dard N and Peter M: Scaffold proteins in
MAP kinase signaling: More than simple passive activating
platforms. BioEssays. 28:146–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cortese MS, Uversky VN and Dunker AK:
Intrinsic disorder in scaffold proteins: Getting more from less.
Prog Biophys Mol Biol. 98:85–106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bumrungthai S, Munjal K, Nandekar S,
Cooper K, Ekalaksananan T, Pientong C and Evans MF: Epidermal
growth factor receptor pathway mutation and expression profiles in
cervical squamous cell carcinoma: Therapeutic implications. J
Transl Med. 13:2442015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Giaccone G: Epidermal growth factor
receptor inhibitors in the treatment of non-small-cell lung cancer.
J Clin Oncol. 23:3235–3242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marquez A, Wu R, Zhao J, Tao J and Shi Z:
Evaluation of epidermal growth factor receptor (EGFR) by
chromogenic in situ hybridization (CISH) and immunohistochemistry
(IHC) in archival gliomas using bright-field microscopy. Diagn Mol
Pathol. 13:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Takehana T, Kunitomo K, Suzuki S, Kono K,
Fujii H, Matsumoto Y and Ooi A: Expression of epidermal growth
factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol.
1:438–445. 2003. View Article : Google Scholar
|
|
44
|
Al-Kuraya K, Schraml P, Torhorst J, Tapia
C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M,
Köchli O, et al: Prognostic relevance of gene amplifications and
coamplifications in breast cancer. Cancer Res. 64:8534–8540. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fallon KB, Palmer CA, Roth KA, Nabors LB,
Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K and Perry A:
Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in
recurrent oligodendrogliomas. J Neuropathol Exp Neurol. 63:314–322.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qureshi R, Arora H, Biswas S, Perwez A,
Naseem A, Wajid S, Gandhi G and Rizvi MA: Mutation analysis of EGFR
and its correlation with the HPV in Indian cervical cancer
patients. Tumour Biol. Jan 14–2016.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
